ID,Title (News Shots),Title 2 (Press Release),"Content 1
 (News Shot)","Content 2
(Newswire.pharmashots.com)
PressRelease",Image URL,Categories,Company Name,Product ,Tags (Inidication|Category|Tags),Status,Date,userID
65022,"PharmaShots Weekly Snapshots (September 27 – October 01, 2021)",,"<!-- wp:paragraph -->
<p><a href=""https://pharmashots.com/wp-admin/post.php?post=65015&amp;action=edit""><strong>BMS Reports EMA’s Validation of MAA for Relatlimab and Nivolumab as 1L Treatment for Unresectable or Metastatic Melanoma</strong></a></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> Oct 1, 2021 | <strong>Tags</strong>: BMS, EMA, MAA, Relatlimab, Nivolumab, Metastatic Melanoma</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><a href=""https://pharmashots.com/wp-admin/post.php?post=65009&amp;action=edit""><strong>Merck and Ridgeback Report Interim Results of Molnupiravir in P-III MOVe-OUT Trial for the Treatment of COVID-19</strong></a></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> Oct 1, 2021 | <strong>Tags:</strong> Merck, Ridgeback, Molnupiravir, P-III, MOVe-OUT Trial, COVID-19</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><a href=""https://pharmashots.com/wp-admin/post.php?post=65003&amp;action=edit""><strong>Sanofi Presents Results of Amlitelimab (KY1005) in P-IIa Study for the Treatment of Moderate-To-Severe Atopic Dermatitis at EADV 2021</strong></a></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> Oct 1, 2021 | <strong>Tags:</strong> Sanofi, Amlitelimab, KY1005, P-IIa, Study, Atopic Dermatitis, EADV 2021</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><a href=""https://pharmashots.com/wp-admin/post.php?post=64996&amp;action=edit""><strong>Dermavant Presented Long-Term Results of Tapinarof in P-III PSOARING 3 Study for the Treatment of Plaque Psoriasis at EADV</strong></a></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> Oct 1, 2021 | <strong>Tags:</strong> Dermavant, Tapinarof, P-III, PSOARING 3 Study, Plaque Psoriasis, EADV</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><a href=""https://pharmashots.com/wp-admin/post.php?post=64994&amp;action=edit""><strong>Novartis Presented Results of Remibrutinib (LOU064) in P-IIb Study for the Treatment of Chronic Spontaneous Urticaria at EADV</strong></a></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> Oct 1, 2021 | <strong>Tags:</strong> Novartis, Remibrutinib, LOU064, P-IIb, Study, Chronic Spontaneous Urticaria, EADV</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><a href=""https://pharmashots.com/wp-admin/post.php?post=64990&amp;action=edit""><strong>Otsuka Enters into a WW License Agreement with Sunovion and Sumitomo Dainippon to Develop and Commercialize Neuropsychiatric Candidates</strong></a></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> Oct 1, 2021 | <strong>Tags:</strong> Otsuka, Sumitomo Dainippon, Neuropsychiatric Compounds</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><a href=""https://pharmashots.com/wp-admin/post.php?post=64974&amp;action=edit""><strong>Merck to Acquire Acceleron for ~$11.5B</strong></a></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> Sept 30, 2021 | <strong>Tags:</strong> Merck, Acquire, Acceleron, ~$11.5B</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><a href=""https://pharmashots.com/wp-admin/post.php?post=64968&amp;action=edit""><strong>Eli Lilly Reports Results of Tirzepatide in P-III SURPASS-3 MRI Sub-Study for the Treatment of Type 2 Diabetes</strong></a></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> Sept 30, 2021 | <strong>Tags:</strong> Eli Lilly, Tirzepatide, P-III, SURPASS-3 MRI Sub-Study, Type 2 Diabetes</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><a href=""https://pharmashots.com/wp-admin/post.php?post=64966&amp;action=edit""><strong>Takeda Signs an Exclusive License Agreement with JCR to Commercialize JR-141 for the Treatment of Hunter Syndrome</strong></a></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> Sept 30, 2021 | <strong>Tags:</strong> Takeda, JCR, JR-141, Hunter Syndrome</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><a href=""https://pharmashots.com/wp-admin/post.php?post=64959&amp;action=edit""><strong>TransMedics’ OCS Liver System Receives the US FDA’s Approval for Liver Transplantation</strong></a></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> Sept 30, 2021 | <strong>Tags:</strong> TransMedics, OCS Liver System, US, FDA, Approval, Livers Transplantation</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><a href=""https://pharmashots.com/wp-admin/post.php?post=64954&amp;action=edit""><strong>Janssen Initiates P-III EVERGREEN Study of RSV Vaccine for the Treatment of Lower Respiratory Tract Disease Due to Respiratory Syncytial Virus</strong></a></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> Sept 30, 2021 | <strong>Tags:</strong> Janssen, P-III, EVERGREEN Study, RSV Vaccine, Lower Respiratory Tract Disease, Respiratory Syncytial Virus</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><a href=""https://pharmashots.com/wp-admin/post.php?post=64949&amp;action=edit""><strong>Regeneron Publishes the Results of REGEN-COV (casirivimab and imdevimab) in P-III Trial for COVID-19 in NEJM</strong></a></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> Sept 30, 2021 | <strong>Tags:</strong> Regeneron, REGEN-COV, casirivimab, imdevimab, P-III, Trial, COVID-19, NEJM</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><a href=""https://pharmashots.com/wp-admin/post.php?post=64935&amp;action=edit""><strong>Medtronic’s Radial Artery Catheter Device Receives CE Mark Approval for the Treatment of Neurovascular Diseases</strong></a></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> Sept 29, 2021 | <strong>Tags:</strong> Medtronic, Radial Artery Catheter Device, CE Mark, Approval, Neurovascular Diseases</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><a href=""https://pharmashots.com/wp-admin/post.php?post=64930&amp;action=edit""><strong>Novartis Reports Results of ligelizumab (QGE031) in P-IIb Study for the Treatment of Chronic Spontaneous Urticaria</strong></a></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> Sept 29, 2021 | <strong>Tags:</strong> Novartis, ligelizumab, QGE031, P-IIb, Study, Chronic Spontaneous Urticaria</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><a href=""https://pharmashots.com/wp-admin/post.php?post=64926&amp;action=edit""><strong>ViiV Healthcare Presents Three-Year Results of Dovato (dolutegravir/lamivudine) in P-III TANGO Study for the Treatment of HIV at IDWeek 2021</strong></a></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> Sept 29, 2021 | <strong>Tags:</strong> ViiV Healthcare, Dovato, dolutegravir, lamivudine, P-III, TANGO Study, HIV, IDWeek 2021</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><a href=""https://pharmashots.com/wp-admin/post.php?post=64921&amp;action=edit""><strong>AstraZeneca to Acquire Caelum for ~500M</strong></a></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> Sept 29, 2021 | <strong>Tags:</strong> AstraZeneca, Acquire, Caelum, ~500M</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><a href=""https://pharmashots.com/wp-admin/post.php?post=64919&amp;action=edit""><strong>AbbVie’s Qulipta (atogepant) Receives the US FDA’s Approval for the Treatment of Migraine</strong></a></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> Sept 29, 2021 | <strong>Tags:</strong> AbbVie, Qulipta, atogepant, US, FDA, Approval, Migraine</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><a href=""https://pharmashots.com/wp-admin/post.php?post=64914&amp;action=edit""><strong>The US FDA Approves New Indication for Lilly’s Erbitux (cetuximab) + Braftovi (encorafenib) to Treat Metastatic Colorectal Cancer with a BRAF V600E Mutation</strong></a></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> Sept 29, 2021 | <strong>Tags:</strong> Lilly, Erbitux, cetuximab, Braftovi, encorafenib, US, FDA, Approval, Metastatic Colorectal Cancer, BRAF V600E Mutation</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><a href=""https://pharmashots.com/wp-admin/post.php?post=64896&amp;action=edit""><strong>Boehringer Ingelheim Signs an Agreement with Invetx to Develop and Commercialize Novel Veterinary Therapies</strong></a></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> Sept 28, 2021 | <strong>Tags:</strong> Boehringer Ingelheim, Invetx, Veterinary Therapies</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><a href=""https://pharmashots.com/wp-admin/post.php?post=64893&amp;action=edit""><strong>ViiV Healthcare Signs an Exclusive License Agreement with Shionogi to Develop S-365598 for HIV</strong></a></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> Sept 28, 2021 | <strong>Tags:</strong> ViiV Healthcare, Shionogi, S-365598, HIV</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><a href=""https://pharmashots.com/wp-admin/post.php?post=64887&amp;action=edit""><strong>Eisai Initiates Rolling Submission of BLA to the US FDA for Lecanemab to Treat Alzheimer’s Disease</strong></a></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> Sept 28, 2021 | <strong>Tags:</strong> Eisai, BLA, US, FDA, Lecanemab, Alzheimer's Disease</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><a href=""https://pharmashots.com/wp-admin/post.php?post=64881&amp;action=edit""><strong>AstraZeneca’s Saphnelo (anifrolumab) Receives MHLW’s Approval for the Treatment of Systemic Lupus Erythematosus</strong></a></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> Sept 28, 2021 | <strong>Tags:</strong> AstraZeneca, Saphnelo, anifrolumab, MHLW, Approval, Systemic Lupus Erythematosus</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><a href=""https://pharmashots.com/wp-admin/post.php?post=64877&amp;action=edit""><strong>Innovent Signs a License Agreement with Union to Develop &amp; Commercialize Orismilast for Inflammatory Dermatology Conditions in China</strong></a></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> Sept 28, 2021 | <strong>Tags:</strong> Innovent, Union, Orismilast, Inflammatory Dermatology Conditions</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><a href=""https://pharmashots.com/wp-admin/post.php?post=64871&amp;action=edit""><strong>Bio-Thera Signs a License Agreement with Intract for Soteria and Phloral Technologies to Develop Oral Antibody Therapies</strong></a></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> Sept 28, 2021 | <strong>Tags:</strong> Bio-Thera, Intract, Soteria, Phloral, Antibody Therapies</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><a href=""https://pharmashots.com/wp-admin/post.php?post=64858&amp;action=edit""><strong>Incyte Enters into an Exclusive WW License Agreement with Syndax to Develop and Commercialize Axatilimab for cGVHD and Other Fibrotic Diseases</strong></a></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> Sept 27, 2021 | <strong>Tags:</strong> Incyte, Syndax, Axatilimab, cGVHD, Fibrotic Diseases</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><a href=""https://pharmashots.com/wp-admin/post.php?post=64847&amp;action=edit""><strong>Takeda’s Alofisel (darvadstrocel) Receives MHLW’s Approval for the Treatment of Complex Perianal Fistulas with Non-active or Mildly Active Luminal CD</strong></a></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> Sept 27, 2021 | <strong>Tags:</strong> Takeda, Alofisel, darvadstrocel, MHLW, Approval, Complex Perianal Fistulas, Active Luminal CD</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><a href=""https://pharmashots.com/wp-admin/post.php?post=64844&amp;action=edit""><strong>Astellas and Seagen’s Padcev (enfortumab vedotin) Receive MHLW’s Approval for the Treatment of Radically Unresectable Urothelial Carcinoma</strong></a></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> Sept 27, 2021 | <strong>Tags:</strong> Astellas, Seagen, Padcev, enfortumab vedotin, MHLW, Approval, Advanced Urothelial Cancer</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><a href=""https://pharmashots.com/wp-admin/post.php?post=64825&amp;action=edit""><strong>JW Reports One-Year Follow-Up Results of Relmacabtagene Autoleucel in P-II RELIANCE Study for the Treatment of R/R LBCL at CSCO 2021</strong></a></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> Sept 27, 2021 | <strong>Tags:</strong> JW, Relmacabtagene Autoleucel, P-II, RELIANCE Study, R/R LBCL, CSCO 2021</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><a href=""https://pharmashots.com/wp-admin/post.php?post=64822&amp;action=edit""><strong>Innovent and AnHeart Report Interim Results of Taletrectinib (AB-106) in P-II TRUST Trial for the Treatment of ROS1-Positive NSCLC at CSCO 2021</strong></a></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> Sept 27, 2021 | <strong>Tags:</strong> Innovent, AnHeart, Taletrectinib, AB-106, P-II, TRUST Trial, ROS1-Positive NSCLC, CSCO 2021</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><a href=""https://pharmashots.com/wp-admin/post.php?post=64813&amp;action=edit""><strong>Amgen’s Repatha (evolocumab) Receives the US FDA’s Approval for the Treatment of Heterozygous Familial Hypercholesterolemia</strong></a></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> Sept 27, 2021 | <strong>Tags:</strong> Amgen, Repatha, evolocumab, US, FDA, Approval, Heterozygous Familial Hypercholesterolemia</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Related Post: <a href=""https://pharmashots.com/64800/pharmashots-weekly-snapshots-september-20-24-2021/"">https://pharmashots.com/64800/pharmashots-weekly-snapshots-september-20-24-2021/</a></strong></p>
<!-- /wp:paragraph -->",,https://pharmashots.com/wp-content/uploads/2021/10/MicrosoftTeams-image-79.jpg,Weekly Snapshot,,,AbbVie|Acceleron|Amgen|AnHeart|Astellas|AstraZeneca|Bio-Thera|BMS|Boehringer Ingelheim|Caelum|Eisai|Eli Lilly|Incyte|Innovent|Intract|Invetx|Janssen|JCR|JW|Lilly|Medtronic|Merck|Novartis|Regeneron|Ridgeback|Seagen|Shionogi|Takeda|TransMedics|Union|ViiV Healthcare,publish,01-10-2021,17
65317,"PharmaShots Weekly Snapshots (October 04 - 08, 2021)",,"<!-- wp:paragraph -->
<p><a href=""https://pharmashots.com/wp-admin/post.php?post=65312&amp;action=edit""><strong>AbbVie’s Rinvoq (upadacitinib) Receives the Health Canada Approval for the Treatment of Moderate to Severe Atopic Dermatitis</strong></a></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> Oct 8, 2021 | <strong>Tags:</strong> AbbVie, Rinvoq, upadacitinib, Health Canada, Approval, Atopic Dermatitis</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><a href=""https://pharmashots.com/wp-admin/post.php?post=65305&amp;action=edit""><strong>Takeda Receives the US FDA Advisory Committee’s Recommendation for TAK-620 (maribavir) to Treat CMV Infection in Post-Transplant Recipients</strong></a></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> Oct 8, 2021 | <strong>Tags:</strong> Takeda, US, FDA, Advisory Committee, Maribavir, TAK-620, CMV Infection</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><a href=""https://pharmashots.com/wp-admin/post.php?post=65292&amp;action=edit""><strong>Allogene Reports the US FDA’s Clinical Hold on ALPHA2 Study of ALLO-501A to Treat Large B Cell Lymphoma</strong></a><strong></strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> Oct 8, 2021 | <strong>Tags:</strong> Allogene, US, FDA, Clinical Hold, ALPHA2 Study, ALLO-501A, Large B Cell Lymphoma</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><a href=""https://pharmashots.com/wp-admin/post.php?post=65287&amp;action=edit""><strong>Sanofi Signs a Non-Exclusive Clinical Collaboration Agreement with Mirati to Evaluate Adagrasib + SAR442720 (RMC-4630) in P-I/II Study for KRAS G12C-Mutated Lung Cancer</strong></a></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> Oct 8, 2021 | <strong>Tags:</strong> Sanofi, Mirati, Adagrasib, SAR442720, RMC-4630, P-I/II, Study, KRAS G12C-Mutated Lung Cancer</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><a href=""https://pharmashots.com/wp-admin/post.php?post=65283&amp;action=edit""><strong>Schrödinger Signs a Two-Year Research Collaboration with MD Anderson to Advance its WEE1 Program</strong></a></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> Oct 8, 2021 | <strong>Tags: </strong>MD Anderson, Schrödinger, WEE1 Program</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><a href=""https://pharmashots.com/wp-admin/post.php?post=65282&amp;action=edit""><strong>AbbVie’s Rinvoq (upadacitinib) Met Primary and Secondary Endpoints in P-III SELECT-AXIS 2 Clinical Trial for Non-Radiographic Axial Spondyloarthritis</strong></a></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> Oct 8, 2021 | <strong>Tags:</strong> AbbVie, Rinvoq, upadacitinib, P-III, SELECT-AXIS 2 Clinical Trial, Non-Radiographic Axial Spondyloarthritis</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><a href=""https://pharmashots.com/wp-admin/post.php?post=65253&amp;action=edit""><strong>BMS’ Deucravacitinib Fails to Meet its Primary and Secondary Endpoints in P-II LATTICE-UC Study for the Treatment of Moderate to Severe Ulcerative Colitis</strong></a></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> Oct 7, 2021 | <strong>Tags:</strong> BMS, Deucravacitinib, P-II, LATTICE-UC Study, Ulcerative Colitis</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><a href=""https://pharmashots.com/wp-admin/post.php?post=65254&amp;action=edit""><strong>Amgen Signs a R&amp;D Collaboration with Neumora to Advance Novel Precision Therapies for Neuropsychiatric and Neurodegenerative Diseases</strong></a></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> Oct 7, 2021 | <strong>Tags:</strong> Amgen, R&amp;D Collaboration, Neumora, Novel Precision Therapies, Neuropsychiatric, Neurodegenerative Diseases</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><a href=""https://pharmashots.com/wp-admin/post.php?post=65246&amp;action=edit""><strong>Denali Presented Results of DNL343 and SAR443820 in P-I Clinical Studies for the Treatment of Amyotrophic Lateral Sclerosis at NEALS 2021</strong></a></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> Oct 7, 2021 | <strong>Tags:</strong> Denali, DNL343, SAR443820, P-I, Clinical Study, Amyotrophic Lateral Sclerosis, NEALS 2021</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><a href=""https://pharmashots.com/wp-admin/post.php?post=65242&amp;action=edit""><strong>PharmaTher Initiates P-II KET-LID Study of Ketamine for Levodopa-Induced Dyskinesia in Patients with Parkinson’s Disease</strong></a></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> Oct 7, 2021 | <strong>Tags:</strong> PharmaTher, P-II, KET-LID Study, Ketamine, Levodopa-Induced Dyskinesia, Parkinson’s Disease</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><a href=""https://pharmashots.com/wp-admin/post.php?post=65236&amp;action=edit""><strong>Sanofi Reports Interim Results of Fluzone High-Dose Quadrivalent Vaccine + COVID-19 mRNA Booster Dose in First Descriptive Study for COVID-19</strong></a></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> Oct 7, 2021 | <strong>Tags:</strong> Sanofi, Fluzone High-Dose Quadrivalent Vaccine, COVID-19 mRNA Booster Dose, Descriptive Study, COVID-19</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><a href=""https://pharmashots.com/wp-admin/post.php?post=65233&amp;action=edit""><strong>Pfizer Signs an Option and License Agreement with Voyager to Develop and Commercialize Gene Therapies for Neurologic and Cardiovascular Diseases</strong></a></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> Oct 7, 2021 | <strong>Tags:</strong> Pfizer, Voyager, Gene Therapies, Neurologic, Cardiovascular Diseases</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><a href=""https://pharmashots.com/wp-admin/post.php?post=65170&amp;action=edit""><strong>Boston to Acquire Baylis for ~$1.75B</strong></a></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> Oct 6, 2021 | <strong>Tags:</strong> Boston, Acquire, ~$1.75B, Electrophysiology, Structural Heart Product Portfolios</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><a href=""https://pharmashots.com/wp-admin/post.php?post=65169&amp;action=edit""><strong>Kaleido Reports Results of KB295 in Clinical and Preclinical Studies for the Treatment of Mild-to-Moderate Ulcerative Colitis</strong></a></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> Oct 6, 2021 | <strong>Tags:</strong> Kaleido, Clinical, KB295, Preclinical Data, Ulcerative Colitis</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><a href=""https://pharmashots.com/wp-admin/post.php?post=65161&amp;action=edit""><strong>Novartis’s Adakveo (crizanlizumab) Receives NICE Recommendation as a New Therapy for Sickle Cell Disease</strong></a></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> Oct 6, 2021 | <strong>Tags:</strong> Novartis, Adakveo, crizanlizumab, NICE, Recommendation, Sickle<strong> Cell Disease</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><a href=""https://pharmashots.com/wp-admin/post.php?post=65152&amp;action=edit""><strong>Sage and Biogen Present Results of Zuranolone in LANDSCAPE and NEST Clinical Development Programs for the Treatment of MDD and PPD at ECNP 2021</strong></a></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> Oct 6, 2021 | <strong>Tags:</strong> Sage, Biogen, Zuranolone, LANDSCAPE, NEST Clinical Development Programs, MDD, PPD, ECNP 2021</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><a href=""https://pharmashots.com/wp-admin/post.php?post=65145&amp;action=edit""><strong>Johnson &amp; Johnson Reports EUA Submission to the US FDA for Supporting the Booster of its Single Shot COVID-19 Vaccine Candidate</strong></a></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> Oct 6, 2021 | <strong>Tags:</strong> Johnson &amp; Johnson, EUA, US, FDA, Single Shot, COVID-19 Vaccine Candidate</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><a href=""https://pharmashots.com/wp-admin/post.php?post=65146&amp;action=edit""><strong>Inotiv to Acquire Plato BioPharma for ~$15.0M</strong></a></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> Oct 6, 2021 | <strong>Tags:</strong> Inotiv, Acquire, Plato BioPharma, ~$15.0M</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><a href=""https://pharmashots.com/wp-admin/post.php?post=65092&amp;action=edit""><strong>Guardant Health Initiates ORACLE Study of Guardant Reveal Blood Test for the Treatment of Early-Stage Cancers</strong></a></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> Oct 5, 2021 | <strong>Tags:</strong> Guardant Health, ORACLE Study, Guardant Reveal Blood Test, Early-Stage Cancers</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><a href=""https://pharmashots.com/wp-admin/post.php?post=65086&amp;action=edit""><strong>Xenon’s XEN1101 Meets its Primary Efficacy Endpoint in P-IIb X-TOLE Clinical Trial for the Treatment of Focal Epilepsy</strong></a></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> Oct 5, 2021 | <strong>Tags:</strong> Xenon, XEN1101, P-IIb, X-TOLE Clinical Trial, Focal Epilepsy</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><a href=""https://pharmashots.com/wp-admin/post.php?post=65080&amp;action=edit""><strong>Coherus Report Results of CHS-201 (biosimilar, ranibizumab) in COLUMBUS-AMD Clinical Trial for the Treatment of nAMD</strong></a></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> Oct 5, 2021 | <strong>Tags:</strong> Coherus, CHS-201, biosimilar, ranibizumab, COLUMBUS-AMD Clinical Trial, nAMD</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><a href=""https://pharmashots.com/wp-admin/post.php?post=65077&amp;action=edit""><strong>AstraZeneca Seeks the US FDA’s EUA for AZD7442 to Treat COVID-19</strong></a></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> Oct 5, 2021 | <strong>Tags:</strong> AstraZeneca, US, FDA, EUA, ZD7442, COVID-19, US</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><a href=""https://pharmashots.com/wp-admin/post.php?post=65075&amp;action=edit""><strong>Polpharma Biologics Reports the US FDA’s Acceptance of BQ201’s (biosimilar, ranibizumab) BLA for Review to Treat Wet Age-Related Macular Degeneration</strong></a></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> Oct 5, 2021 | <strong>Tags:</strong> Polpharma Biologics, US, FDA, Acceptance, BQ201, biosimilar, ranibizumab, BLA, Wet Age-Related Macular Degeneration</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><a href=""https://pharmashots.com/wp-admin/post.php?post=65070&amp;action=edit""><strong>Takeda Enters into a License Agreement with Selecta to Develop Gene Therapies for the Treatment of Lysosomal Storage Disorders</strong></a></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> Oct 5, 2021 | <strong>Tags:</strong> Takeda, Selecta, Gene Therapies, Lysosomal Storage Disorders</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><a href=""https://pharmashots.com/wp-admin/post.php?post=65052&amp;action=edit""><strong>Xencor Enter into an Exclusive WW License Agreement with Janssen to Develop and Commercialize Plamotamab and Xmab CD28 Bispecific Antibody for B-Cell Malignancies</strong></a></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> Oct 4, 2021 | <strong>Tags:</strong> Xencor, Janssen, Plamotamab, Xmab B-Cell, B-Cell Malignancies</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><a href=""https://pharmashots.com/wp-admin/post.php?post=65050&amp;action=edit""><strong>ViiV Healthcare Submits Regulatory Applications to the US FDA for a New Dispersible Tablet Formulation of Abacavir/Dolutegravir/Lamivudine to Treat HIV in Children</strong></a></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> Oct 4, 2021 | <strong>Tags:</strong> ViiV Healthcare, US, FDA, Triumeq, abacavir, dolutegravir, lamivudine, Approval, HIV</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><a href=""https://pharmashots.com/wp-admin/post.php?post=65045&amp;action=edit""><strong>Janssen Presented Results of RSV Vaccine in P-IIb CYPRESS Study for Lower Respiratory Tract Disease Due to Respiratory Syncytial Virus at IDWeek 2021</strong></a></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> Oct 4, 2021 | <strong>Tags:</strong> Janssen, RSV Vaccine, P-IIb, CYPRESS Study, Lower Respiratory Tract Disease, Respiratory Syncytial Virus, IDWeek 2021</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><a href=""https://pharmashots.com/wp-admin/post.php?post=65041&amp;action=edit""><strong>Formycon and Bioeq Report the US FDA’s Acceptance of BLA for FYB201 (biosimilar, ranibizumab)</strong></a></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> Oct 4, 2021 | <strong>Tags:</strong> Formycon, Bioeq, US, FDA, Acceptance, BLA, FYB201, biosimilar, ranibizumab</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><a href=""https://pharmashots.com/wp-admin/post.php?post=65033&amp;action=edit""><strong>Merck KGaA and GSK Terminate their ~$4.2B Collaboration Due to Clinical Failures</strong></a></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> Oct 4, 2021 | <strong>Tags:</strong> Merck KGaA, GSK, ~$4.2B,</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><a href=""https://pharmashots.com/wp-admin/post.php?post=65029&amp;action=edit""><strong>Kite’s Tecartus Receives the US FDA’s Approval as the First and Only Car T for Adults with Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia</strong></a></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> Oct 4, 2021 | <strong>Tags:</strong> Kite, Tecartus, US, FDA, Approval, Car T, Refractory B-cell Acute Lymphoblastic Leukemia</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Related Post:</strong> <strong><a href=""https://pharmashots.com/65022/pharmashots-weekly-snapshots-september-27-october-01-2021/"">PharmaShots Weekly Snapshots (September 27 – October 01, 2021)</a></strong></p>
<!-- /wp:paragraph -->",,https://pharmashots.com/wp-content/uploads/2021/10/MicrosoftTeams-image-92.jpg,Weekly Snapshot,,,AbbVie|Allogene|Amgen|AstraZeneca|Bioeq|Biogen|BMS|Boston|Coherus|Denali|Formycon|GSK|Guardant Health|Inotiv|Janssen|Johnson &amp; Johnson|Kaleido|Kite|MD Anderson|Merck KGaA|Mirati|Novartis|Pfizer|PharmaTher|Plato BioPharma|Polpharma Biologics|Sage|Sanofi|Schrödinger|Selecta|Takeda|ViiV Healthcare|Xencor|Xenon,publish,08-10-2021,17
65520,"PharmaShots Weekly Snapshots (October 11 – 15, 2021)",,"<!-- wp:paragraph -->
<p></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong><a href=""https://pharmashots.com/65515/bristol-myers-squibbs-zeposia-ozanimod-receives-chmps-positive-opinion-for-adult-patients-with-moderately-to-severely-active-ulcerative-colitis/""><strong>Bristol Myers Squibb’s Zeposia (ozanimod) Receives CHMP’s Positive Opinion for Adult Patients with Moderately to Severely Active Ulcerative Colitis</strong></a></strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> 15 Oct, 2021 <strong>| Tags:</strong> Bristol Myers Squibb, Zeposia, ozanimod, CHMP, Positive Opinion, Adult Patients with Moderately to Severely Active Ulcerative Colitis</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong><a href=""https://pharmashots.com/65508/gan-lee-completes-p-iii-studies-of-gl-gla-for-patients-with-t1d-t2d/""><strong>Gan &amp; Lee Completes P-III Studies of GL-GLA for Patients with T1D &amp; T2D</strong></a></strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> 15 Oct, 2021 <strong>| Tags:</strong> Gan &amp; Lee, P-III, GL-GLA, T1D, T2D</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong><a href=""https://pharmashots.com/65505/exelixis-in-licenses-second-anti-cancer-compound-from-aurigene-following-the-us-fdas-acceptance-of-ind-for-p-i-study-of-xl114-in-non-hodgkins-lymphoma/""><strong>Exelixis</strong><strong> </strong><strong>In-Licenses Second Anti-Cancer Compound from Aurigene Following the US FDA’s Acceptance of IND for P-I Study of XL114 in Non-Hodgkin’s Lymphoma</strong></a></strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> 15 Oct, 2021 <strong>| Tags:</strong> Exelixis, Aurigene, US, FDA, Acceptance, IND, P-I Study, XL114, Non-Hodgkin’s Lymphoma</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong><a href=""https://pharmashots.com/65495/hologic-to-acquire-bolder-surgical-for-160m/""><strong>Hologic to Acquire Bolder Surgical for $160M</strong></a></strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> 15 Oct, 2021 <strong>| Tags:</strong> Hologic, Acquire, Bolder Surgical, $160M, NovaSure, MyoSure tissue removal devices, Acessa laparoscopic radiofrequency ablation system</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong><a href=""https://pharmashots.com/65490/astrazeneca-reports-results-of-imfinzi-tremelimumab-in-p-iii-himalaya-study-for-1l-treatment-of-unresectable-liver-cancer/""><strong>AstraZeneca Reports Results of Imfinzi + Tremelimumab in P-III HIMALAYA Study for 1L Treatment of Unresectable Liver Cancer</strong></a></strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> 15 Oct, 2021 <strong>| Tags:</strong> AstraZeneca, Imfinzi, Tremelimumab, P-III, HIMALAYA Study, 1L, Treatment, Unresectable Liver Cancer</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong><a href=""https://pharmashots.com/65485/lilly-presents-updated-data-of-verzenio-abemaciclib-in-p-iii-monarche-trial-presented-at-esmo-and-published-in-the-annals-of-oncology/""><strong>Lilly Presents Updated Data of Verzenio (abemaciclib) in P-III monarchE Trial Presented at ESMO and Published in the Annals of Oncology</strong></a></strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> 15 Oct, 2021 <strong>| Tags:</strong> Lilly, Verzenio, abemaciclib, P-III, monarchE Trial, ESMO, Annals of Oncology</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong><a href=""https://pharmashots.com/65466/regeneron-reports-the-us-fdas-acceptance-of-priority-review-for-regen-cov-for-the-treatment-and-prophylaxis-of-covid-19/""><strong>Regeneron Reports the US FDA’s Acceptance of Priority Review for REGEN-COV for the Treatment and Prophylaxis of COVID-19</strong></a></strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> 14 Oct, 2021 <strong>| Tags:</strong> Regeneron, US, FDA, Acceptance, Priority Review, REGEN-COV, COVID-19</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong><a href=""https://pharmashots.com/65467/asieris-receives-nmpas-ind-approval-to-evaluate-apl-1202-tislelizumab-as-neoadjuvant-therapy-for-mibc-patients/"">Asieris Receives NMPA’s IND Approval to Evaluate APL-1202 + Tislelizumab as Neoadjuvant Therapy for MIBC Patients</a></strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> 14 Oct, 2021 <strong>| Tags:</strong> Asieris, NMPA, IND Approval, APL-1202, Tislelizumab, Neoadjuvant Therapy, MIBC</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong><a href=""https://pharmashots.com/65464/novartis-reports-the-us-fda-and-ema-filing-acceptance-of-beovu-for-patients-with-diabetic-macular-edema/""><strong>Novartis Reports the US FDA and EMA Filing Acceptance of Beovu for Patients with Diabetic Macular Edema</strong></a></strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> 14 Oct, 2021 <strong>| Tags:</strong> Novartis, US, FDA, EMA, Beovu, Diabetic Macular Edema</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong><a href=""https://pharmashots.com/65457/mercks-keytruda-pembrolizumab-receives-the-us-fdas-approval-for-second-indication-in-cervical-cancer/""><strong>Merck’s Keytruda (pembrolizumab) Receives the US FDA’s Approval for</strong><strong> </strong><strong>Second Indication in Cervical Cancer</strong></a></strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> 14 Oct, 2021 <strong>| Tags:</strong> Merck, Keytruda, pembrolizumab, US, FDA, Approval, Second Indication, Cervical Cancer</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong><a href=""https://pharmashots.com/65452/turning-point-and-eqrx-collaborate-to-evaluate-elzovantinib-aumolertinib-in-patients-with-egfr-mutant-met-amplified-advanced-nsclc/"">Turning Point and EQRx Collaborate to Evaluate Elzovantinib + Aumolertinib in Patients with EGFR Mutant Met-Amplified Advanced NSCLC</a></strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> 14 Oct, 2021 <strong>| Tags:</strong> Turning Point, Elzovantinib, Aumolertinib, NSCLC</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong><a href=""https://pharmashots.com/65451/pharmathers-ketamine-receives-the-us-fdas-orphan-drug-designation-for-complex-regional-pain-syndrome/""><strong>PharmaTher’s Ketamine Receives the US FDA’s Orphan Drug Designation for Complex Regional Pain Syndrome</strong></a></strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> 14 Oct, 2021 <strong>| Tags:</strong> PharmaTher, Ketamine, US, FDA, Orphan Drug Designation,&nbsp; Complex Regional Pain Syndrome</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong><a href=""https://pharmashots.com/65427/eli-lillys-verzenio-abemaciclib-receives-the-us-fdas-approval-for-people-with-hr-her2-high-risk-early-breast-cancer/""><strong>Eli Lilly’s Verzenio (abemaciclib) Receives the US FDA’s Approval for People with HR+ HER2- High Risk Early Breast Cancer</strong></a></strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> 13 Oct, 2021 <strong>| Tags:</strong> Eli Lilly, Verzenio, abemaciclib, US, FDA, Approval, HR+, HER2-, High Risk Early Breast Cancer</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong><a href=""https://pharmashots.com/65428/sanofis-sarclisa-combination-regimen-receives-health-canadas-approval-for-multiple-myeloma/""><strong>Sanofi's Sarclisa Combination Regimen Receives Health Canada’s Approval for Multiple Myeloma</strong></a></strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> 13 Oct, 2021 <strong>| Tags:</strong> Sanofi, Sarclisa, Combination Regimen, Health Canada, Approval, Multiple Myeloma</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong><a href=""https://pharmashots.com/65422/sanofi-presents-results-of-tolebrutinib-in-a-p-iib-lts-for-relapsing-forms-of-multiple-sclerosis-at-ectrims-2021/"">Sanofi Presents Results of Tolebrutinib in a P-IIb LTS for Relapsing Forms of Multiple Sclerosis at ECTRIMS 2021</a></strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> 13 Oct, 2021 <strong>| Tags:</strong> Sanofi, Tolebrutinib, P-IIb, LTS, Relapsing Forms of Multiple Sclerosis, ECTRIMS 2021</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong><a href=""https://pharmashots.com/65418/ultimovacs-reports-results-of-24-month-follow-up-study-of-uv1-pembrolizumab-for-1l-treatment-of-metastatic-malignant-melanoma/""><strong>Ultimovacs Reports Results of 24-month Follow-up Study of UV1 + Pembrolizumab for 1L Treatment of Metastatic Malignant Melanoma</strong></a></strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> 13 Oct, 2021 <strong>| Tags:</strong> Ultimovacs, UV1, Pembrolizumab, Metastatic Malignant Melanoma</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong><a href=""https://pharmashots.com/65410/spark-signs-an-exclusive-global-licensing-agreement-with-combigene-for-cg01-to-treat-focal-epilepsy/""><strong>Spark Signs an Exclusive Global Licensing Agreement with CombiGene for CG01 to Treat Focal Epilepsy</strong></a></strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> 13 Oct, 2021 <strong>| Tags:</strong> Spark, CombiGene, CG01, Focal Epilepsy, develop, manufacture, commercialize</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong><a href=""https://pharmashots.com/65409/takeda-signs-an-exclusive-license-agreement-with-poseida-for-novel-non-viral-in-vivo-gene-therapies/""><strong>Takeda Signs an Exclusive License Agreement with Poseida for Novel Non-Viral In Vivo Gene Therapies</strong></a></strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> 13 Oct, 2021 <strong>| Tags:</strong> Takeda, License Agreement, Poseida, Non-Viral In Vivo Gene Therapies</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong><a href=""https://pharmashots.com/65383/sutro-signs-an-option-agreement-with-bionova-to-develop-and-commercialize-stro-001-for-hematologic-cancers-in-greater-china/"">Sutro Signs an Option Agreement with BioNova to Develop and Commercialize STRO-001 for Hematologic Cancers in Greater China</a></strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> 12 Oct, 2021 <strong>| Tags:</strong> BioNova, Greater China, Hematologic Cancers, Option Agreement, STRO-001, Sutro</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong><a href=""https://pharmashots.com/65384/the-us-fda-lifts-the-clinical-hold-of-protagonists-rusfertide-clinical-development-program/"">The US FDA Lifts the Clinical Hold of Protagonist’s Rusfertide Clinical Development Program</a></strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> 12 Oct, 2021 <strong>| Tags:</strong> Clinical Hold, FDA, Protagonist, Rusfertide Clinical Development Program, US</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong><a href=""https://pharmashots.com/65377/abcellera-enters-into-a-collaboration-and-license-agreement-with-salipro-to-boost-therapeutic-antibodies/"">AbCellera Enters into a Collaboration and License Agreement with Salipro to Boost Therapeutic Antibodies</a></strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> 12 Oct, 2021 <strong>| Tags:</strong> AbCellera, Salipro, Therapeutic Antibodies</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong><a href=""https://pharmashots.com/65368/sarepta-presents-the-new-analyses-and-functional-data-of-srp-9001-in-multiple-studies-for-the-treatment-of-dmd-at-srp-9001-micro-dystrophin-day/"">Sarepta Presents the New Analyses and Functional Data of SRP-9001 in Multiple Studies for the Treatment of DMD at SRP-9001 Micro-dystrophin Day</a></strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> 12 Oct, 2021 <strong>| Tags:</strong> DMD, Multiple studies, Sarepta, SRP-9001, SRP-9001 Micro-dystrophin Day</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong><a href=""https://pharmashots.com/65364/pacira-to-acquire-flexion-for-427m/"">Pacira to Acquire Flexion for ~427M</a></strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> 12 Oct, 2021 <strong>| Tags:</strong> ~427M, Acquire, Flexion, Pacira</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong><a href=""https://pharmashots.com/65363/astrazenecas-azd7442-meet-its-primary-endpoints-in-p-iii-tackle-trial-for-the-treatment-of-covid-19/"">AstraZeneca’s AZD7442 Meet its Primary Endpoints in P-III TACKLE Trial for the Treatment of COVID-19</a></strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> 12 Oct, 2021 <strong>| Tags:</strong> AstraZeneca, AZD7442, COVID-19, P-III, TACKLE Trial</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong><a href=""https://pharmashots.com/65347/supernus-to-acquire-adamas-for-450m/"">Supernus to Acquire Adamas for ~$450M</a></strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> 11 Oct, 2021 <strong>| Tags:</strong> ~$450M, Acquire, Adamas, Supernus</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong><a href=""https://pharmashots.com/65344/merck-and-ridgeback-report-eua-submission-to-the-us-fda-for-molnupiravir-to-treat-covid-19/"">Merck and Ridgeback Report EUA Submission to the US FDA for Molnupiravir to Treat COVID-19</a></strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> 11 Oct, 2021 <strong>| Tags:</strong> COVID-19, EUA, FDA, Merck, Molnupiravir, Ridgeback, US</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong><a href=""https://pharmashots.com/65338/regenxbio-presents-results-of-rgx-314-in-p-ii-altitude-trial-for-the-treatment-of-diabetic-retinopathy-at-asrs-annual-meeting/"">Regenxbio Presents Results of RGX-314 in P-II ALTITUDE Trial for the Treatment of Diabetic Retinopathy at ASRS Annual Meeting</a></strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> 11 Oct, 2021 <strong>| Tags:</strong> ALTITUDE Trial, ASRS Annual Meeting, Diabetic Retinopathy, P-II, Regenxbio, RGX-314</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong><a href=""https://pharmashots.com/65332/turning-point-presents-results-of-repotrectinib-in-p-i-ii-trident-1-study-for-the-treatment-of-solid-tumors-at-aacr-nci-eortc-2021/"">Turning Point Presents Results of Repotrectinib in P-I/II TRIDENT-1 Study for the Treatment of Solid Tumors at AACR-NCI-EORTC 2021</a></strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> 11 Oct, 2021 <strong>| Tags:</strong> AACR-NCI-EORTC 2021, P-I/II, Repotrectinib, Solid Tumors, TRIDENT-1 Study, Turning Point</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong><a href=""https://pharmashots.com/65328/genentechs-gantenerumab-receives-the-us-fdas-breakthrough-therapy-designation-for-the-treatment-of-alzheimers-disease/"">Genentech’s Gantenerumab Receives the US FDA’s Breakthrough Therapy Designation for the Treatment of Alzheimer’s Disease</a></strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> 11 Oct, 2021 <strong>| Tags:</strong> Alzheimer’s Disease, Breakthrough Therapy Designation, FDA, Gantenerumab, Genentech, US</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong><a href=""https://pharmashots.com/65325/janssen-report-submission-of-sbla-to-the-us-fda-for-the-approval-of-stelara-ustekinumab-to-treat-juvenile-psoriatic-arthritis/"">Janssen Report Submission of sBLA to the US FDA for the Approval of Stelara (ustekinumab) to Treat Juvenile Psoriatic Arthritis</a></strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> 11 Oct, 2021 <strong>| Tags:</strong> FDA, Janssen, Juvenile Psoriatic Arthritis, sBLA, Stelara, US, ustekinumab</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Related Post: <a href=""https://pharmashots.com/65317/pharmashots-weekly-snapshots-october-04-08-2021/"">PharmaShots Weekly Snapshots (October 04 – 08, 2021)</a></strong></p>
<!-- /wp:paragraph -->",,https://pharmashots.com/wp-content/uploads/2021/10/Image20211015183222.jpg,Weekly Snapshot,,,AbCellera|Adamas|Asieris|AstraZeneca|Aurigene|BioNova|Bolder Surgical|Bristol Myers Squibb|CombiGene|Eli Lilly|Exelixis|Flexion|Gan &amp; Lee|Genentech|Hologic|Janssen|Lilly|Merck|Novartis|Pacira|PharmaTher|Protagonist|Regeneron|Regenxbio|Repotrectinib|Salipro|Sanofi|Sarclisa|Spark|Supernus|Takeda|Turning Point|Ultimovacs|US|Verzenio,publish,15-10-2021,17
65735,"PharmaShots Weekly Snapshots (October 18 – 22, 2021)",,"<!-- wp:paragraph -->
<p><a href=""https://pharmashots.com/wp-admin/post.php?post=65713&amp;action=edit""><strong>LEO Reports 16-week Results of Tralokinumab in P-III ECZTRA 6 Trial for the Treatment of Moderate-to-Severe Atopic Dermatitis</strong></a></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> 22 Oct, 2021 | <strong>Tags:</strong> LEO, Tralokinumab, P-III, ECZTRA 6 Trial, Atopic Dermatitis</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><a href=""https://pharmashots.com/wp-admin/post.php?post=65714&amp;action=edit""><strong>Marinomed Biotech Signs a License Agreement with Luoxin to Commercialize Budesolv (budesonide nasal spray) in Greater China</strong></a></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> 22 Oct, 2021 | <strong>Tags:</strong> Marinomed Biotech, Luoxin, Budesolv, budesonide nasal spray, Greater China</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><a href=""https://pharmashots.com/wp-admin/post.php?post=65709&amp;action=edit""><strong>Regeneron and Sanofi Report Results of Dupixent (dupilumab) in P-III PRIME2 Trial for the Treatment of Prurigo Nodularis</strong></a></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> 22 Oct, 2021 | <strong>Tags:</strong> Regeneron, Sanofi, Dupixent, dupilumab, P-III PRIME2, Trial, Prurigo Nodularis</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><a href=""https://pharmashots.com/wp-admin/post.php?post=65700&amp;action=edit""><strong>Scynexis Reports Results of Ibrexafungerp in P-III VANISH-303 Trial for Treatment of Vaginal Yeast Infection</strong></a></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> 22 Oct, 2021 | <strong>Tags:</strong> Scynexis, Ibrexafungerp, P-III, VANISH-303 Trial, Vaginal Yeast Infection</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><a href=""https://pharmashots.com/wp-admin/post.php?post=65694&amp;action=edit""><strong>Selecta Enters into an Exclusive License Agreement with Genovis to Advance IgG Protease in Gene Therapy and Autoimmune Disease</strong></a></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> 22 Oct, 2021 | <strong>Tags:</strong> Selecta, Genovis, IgG Protease, Gene Therapy, Autoimmune Disease</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><a href=""https://pharmashots.com/wp-admin/post.php?post=65695&amp;action=edit""><strong>Incyte Enters into a Supply Agreement with Specialised Therapeutics to Launch Tafasitamab and Pemigatinib in Australia and Other Countries</strong></a></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> 22 Oct, 2021 | <strong>Tags:</strong> Incyte, Specialised Therapeutics, Tafasitamab and Pemigatinib in Australia, New Zealand and Singapore</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><a href=""https://pharmashots.com/wp-admin/post.php?post=65672&amp;action=edit""><strong>Pfizer and BioNTech Report Results of COVID-19 Vaccine Booster in P-III Trial for the Treatment of COVID-19</strong></a></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> 21 Oct, 2021 | <strong>Tags:</strong> Pfizer, BioNTech, COVID-19 Vaccine, Booster, P-III, Trial, COVID-19</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><a href=""https://pharmashots.com/wp-admin/post.php?post=65673&amp;action=edit""><strong>Pfizer’s Prevnar 20 (Pneumococcal 20-Valent Conjugate Vaccine) Receives the CDC’s Advisory Committee Recommendation for Invasive Disease and Pneumonia</strong></a></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> 21 Oct, 2021 | <strong>Tags:</strong> Pfizer, Prevnar 20, Pneumococcal 20-Valent Conjugate Vaccine, CDC, Advisory Committee, Invasive Disease, Pneumonia</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><a href=""https://pharmashots.com/wp-admin/post.php?post=65674&amp;action=edit""><strong>Antengene Enters into a Research Collaboration &amp; License Option Agreement with LegoChem Biosciences for Antibody-Drug Conjugate Candidates</strong></a></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> 21 Oct, 2021 | <strong>Tags:</strong> Antengene, LegoChem Biosciences, Antibody-Drug Conjugate Candidates</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><a href=""https://pharmashots.com/wp-admin/post.php?post=65663&amp;action=edit""><strong>Regeneron and Sanofi’s Dupixent (dupilumab) Receive the US FDA’s Approval as an Add-On Maintenance Treatment to Treat Moderate-To-Severe Asthma</strong></a></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> 21 Oct, 2021 | <strong>Tags:</strong> Regeneron, Sanofi, Dupixent, dupilumab, US, FDA, Approval, Asthma</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><a href=""https://pharmashots.com/wp-admin/post.php?post=65657&amp;action=edit""><strong>Sumitomo Dainippon Pharma Signs a Definitive Agreement with BehaVR to Develop and Commercialize PDTs and Wellness Product for CNS Disorders</strong></a></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> 21 Oct, 2021 | <strong>Tags:</strong> Sumitomo Dainippon Pharma, BehaVR, Prescription Digital Therapeutics, CNS Disorders</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><a href=""https://pharmashots.com/wp-admin/post.php?post=65652&amp;action=edit""><strong>Janssen Enters into a License and Collaboration Agreement with F-star to Develop and Commercialize Multiple Bispecific Antibody Therapeutics</strong></a></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> 21 Oct, 2021 | <strong>Tags:</strong> Janssen, F-star, Multiple, Bispecific, Antibody Therapeutics</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><a href=""https://pharmashots.com/wp-admin/post.php?post=65625&amp;action=edit""><strong>Dicerna Reports Results of Nedosiran in PHYOX4 Study for the Treatment of Primary Hyperoxaluria Type 3</strong></a></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> 20 Oct, 2021 | <strong>Tags:</strong> Dicerna, Nedosiran, PHYOX4 Study, Primary Hyperoxaluria Type 3</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><a href=""https://pharmashots.com/wp-admin/post.php?post=65626&amp;action=edit""><strong>SpringWorks Enters into an Exclusive WW License Agreement with Academic Institutions to Advance Portfolio of Mutation-Selective EGFR Inhibitors</strong></a></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> 20 Oct, 2021 | <strong>Tags:</strong> SpringWorks, Academic Institutions, Portfolio, Mutation-Selective, EGFR Inhibitors</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><a href=""https://pharmashots.com/wp-admin/post.php?post=65616&amp;action=edit""><strong>Atea Reports Results of AT-527 in P-II MOONSONG Trial for the Treatment of COVID-19</strong></a></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> 20 Oct, 2021 | <strong>Tags:</strong> Atea, AT-527, P-II, MOONSONG Trial, COVID-19</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><a href=""https://pharmashots.com/wp-admin/post.php?post=65606&amp;action=edit""><strong>Sana Entered into an Agreement with Beam for Non-Exclusive Commercial Rights of its CRISPR Cas12b Nuclease System for Cell Therapy Programs</strong></a></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> 20 Oct, 2021 | <strong>Tags:</strong> Sana, Beam, CRISPR, Cas12b Nuclease System, Cell Therapy Programs</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><a href=""https://pharmashots.com/wp-admin/post.php?post=65607&amp;action=edit""><strong>Antios Enters into a Clinical Collaboration Agreement with Assembly Biosciences to Evaluate ATI-2173 and Vebicorvir for Chronic Hepatitis B Virus Infection</strong></a></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> 20 Oct, 2021 | <strong>Tags:</strong> Antios, Assembly Biosciences, ATI-2173, Vebicorvir, Chronic Hepatitis B Virus Infection</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><a href=""https://pharmashots.com/wp-admin/post.php?post=65608&amp;action=edit""><strong>Boehringer Ingelheim Exercised its Option to License Oxford Biomedica’s Lentiviral Vector Technology to Commercialize BI 3720931 for CF</strong></a></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> 20 Oct, 2021 | <strong>Tags:</strong> Boehringer Ingelheim, License, Oxford Biomedica, Lentiviral Vector Technology, BI 3720931, CF</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><a href=""https://pharmashots.com/wp-admin/post.php?post=65587&amp;action=edit""><strong>Lilly Published Results of Tirzepatide in SURPASS-4 Study for the Treatment of Type 2 Diabetes in The Lancet</strong></a></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> 19 Oct, 2021 | <strong>Tags:</strong> Lilly, Tirzepatide, SURPASS-4 Study, Type 2 Diabetes, The Lancet</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><a href=""https://pharmashots.com/wp-admin/post.php?post=65588&amp;action=edit""><strong>Sanofi’s Dupixent (dupilumab) Receives NICE Recommendation for the Treatment of Severe Asthma</strong></a></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> 19 Oct, 2021 | <strong>Tags:</strong> Sanofi, Dupixent, dupilumab, NICE, Severe Asthma</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><a href=""https://pharmashots.com/wp-admin/post.php?post=65578&amp;action=edit""><strong>Takeda Signs an Agreement with Calithera to Acquire Sapanisertib and Mivavotinib</strong></a></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> 19 Oct, 2021 | <strong>Tags:</strong> Takeda, Calithera, Acquire, Sapanisertib, Mivavotinib</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><a href=""https://pharmashots.com/wp-admin/post.php?post=65574&amp;action=edit""><strong>Gilead’s Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) Low-Dose Tablet Receives the US FDA’s Approval for Expanded Indication to Treat HIV-1</strong></a></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> 19 Oct, 2021 | <strong>Tags:</strong> Gilead, Biktarvy, bictegravir, emtricitabine, tenofovir alafenamide, US, FDA, Approval, HIV-1</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><a href=""https://pharmashots.com/wp-admin/post.php?post=65568&amp;action=edit""><strong>Takeda Amend its Collaboration with Wave Life Sciences to Advance CNS Programs</strong></a></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> 19 Oct, 2021 | <strong>Tags:</strong> Takeda, Wave Life Sciences, CNS Programs</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><a href=""https://pharmashots.com/wp-admin/post.php?post=65569&amp;action=edit""><strong>Lipocine Enters into an Exclusive License Agreement with Antares to Commercialize Tlando in the US</strong></a></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> 19 Oct, 2021 | <strong>Tags:</strong> Lipocine, Antares, Tlando, US</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><a href=""https://pharmashots.com/wp-admin/post.php?post=65548&amp;action=edit""><strong>Innovent Reports Results of Sintilimab in P-III ORIENT-31 Study for EGFR-Mutated Non squamous Non-Small Cell Lung Cancer</strong></a></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> 18 Oct, 2021 | <strong>Tags:</strong> Innovent, Sintilimab, P-III, ORIENT-31 Study, EGFR-Mutated, Non squamous, Non-Small Cell Lung Cancer</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><a href=""https://pharmashots.com/wp-admin/post.php?post=65549&amp;action=edit""><strong>Ipsen Signs an Exclusive WW Collaboration with Accent to Develop and Commercialize METTL3 Program</strong></a></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> 18 Oct, 2021 | <strong>Tags: </strong>Ipsen, Accent, METTL3 program, AML</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><a href=""https://pharmashots.com/wp-admin/post.php?post=65541&amp;action=edit""><strong>Bio-Thera Expands its Partnership with Pharmapark to Commercialize BAT2206 (biosimilar, ustekinumab in Russia and other CIS Countries</strong></a></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> 18 Oct, 2021 | <strong>Tags: </strong>Bio-Thera, Pharmapark, BAT2206, biosimilar, ustekinumab, Russia, CIS Countries</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><a href=""https://pharmashots.com/wp-admin/post.php?post=65537&amp;action=edit""><strong>Boehringer Ingelheim’s Cyltezo (biosimilar, adalimumab) Receives the US FDA’s sBLA Approval as the 1st Interchangeable Biosimilar for Multiple Chronic Inflammatory Diseases</strong></a></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> 18 Oct, 2021 | <strong>Tags: </strong>Boehringer Ingelheim, Cyltezo, biosimilar, adalimumab, US, FDA, sBLA, Approval, Inflammatory diseases</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><a href=""https://pharmashots.com/wp-admin/post.php?post=65530&amp;action=edit""><strong>AbbVie’ Skyrizi (risankizumab) Receives CHMP’s Positive Opinion for the Treatment of Adults with Active Psoriatic Arthritis in the EU</strong></a></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> 18 Oct, 2021 | <strong>Tags: </strong>AbbVie, Skyrizi, Risankizumab, CHMP, Active Psoriatic Arthritis, EU</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><a href=""https://pharmashots.com/wp-admin/post.php?post=65529&amp;action=edit""><strong>Genentech’s Tecentriq Receives the US FDA’s Approval as Adjuvant Treatment for Early Non-Small Cell Lung Cancer</strong></a></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> 18 Oct, 2021 | <strong>Tags: </strong>Genentech, Tecentriq, US, FDA, Approval, Non-Small Cell Lung Cancer</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Related Post:</strong> <strong><a href=""https://pharmashots.com/65520/pharmashots-weekly-snapshots-october-11-15-2021/"">PharmaShots Weekly Snapshots (October 11 – 15, 2021)</a></strong></p>
<!-- /wp:paragraph -->",,https://pharmashots.com/wp-content/uploads/2021/10/MicrosoftTeams-image-108.jpg,Weekly Snapshot,,,AbbVie|Academic Institutions|Accent|Antares|Antengene|Antios|Assembly Biosciences|Atea|Beam|BehaVR|Bio-Thera|BioNTech|Boehringer Ingelheim|Calithera|Dicerna|F-star|Genentech|Genovis|Gilead|Incyte|Innovent|Ipsen|Janssen|LegoChem Biosciences|LEO|Lilly|Lipocine|Luoxin|Marinomed Biotech|Oxford BioMedica|Pfizer|Pharmapark|Regeneron|Sana|Sanofi|Scynexis|Selecta|Specialised Therapeutics|SpringWorks|Sumitomo Dainippon Pharma|Takeda|Wave Life Sciences,publish,22-10-2021,17
65986,"PharmaShots Weekly Snapshots (October 25 – 29, 2021)",,"<!-- wp:paragraph -->
<p><a href=""https://pharmashots.com/wp-admin/post.php?post=65982&amp;action=edit""><strong>ADC Reports EMA’s Validation of MAA for Zynlonta to Treat R/R Diffuse Large B-Cell Lymphoma</strong></a></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> Oct 29, 2021 | <strong>Tags:</strong> ADC, EMA, MAA, Zynlonta, R/R Diffuse Large B-Cell Lymphoma</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><a href=""https://pharmashots.com/wp-admin/post.php?post=65976&amp;action=edit""><strong>Impact Receives US FDA’s IND Clearance for IMP9064 to Treat Solid Tumor</strong></a></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> Oct 29, 2021 | <strong>Tags:</strong> Impact, US, FDA, IND, IMP9064, Solid Tumor</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><a href=""https://pharmashots.com/wp-admin/post.php?post=65972&amp;action=edit""><strong>Novartis Reports the US FDA and EMA’s Acceptance of sBLA for Kymriah (tisagenlecleucel) and Granted Priority Review to Treat R/R Follicular Lymphoma</strong></a></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> Oct 29, 2021 | <strong>Tags:</strong> Novartis, US, FDA, EMA, sBLA, Kymriah, Tisagenlecleucel, Priority Review, R/R Follicular Lymphoma</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><a href=""https://pharmashots.com/wp-admin/post.php?post=65968&amp;action=edit""><strong>AbbVie Reports Results of ABBV-951 (foslevodopa/foscarbidopa) in P-III M15-736 Study for the Treatment of Advanced Parkinson’s Disease</strong></a></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> Oct 29, 2021 | <strong>Tags:</strong> AbbVie, ABBV-951, foslevodopa, foscarbidopa, P-III, M15-736 Study, Advanced Parkinson's Disease</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><a href=""https://pharmashots.com/wp-admin/post.php?post=65955&amp;action=edit""><strong>Kite’s Tecartus (brexucabtagene autoleucel) Receives Health Canada’s Approval for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma</strong></a></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> Oct 29, 2021 | <strong>Tags:</strong> Kite, Tecartus, brexucabtagene autoleucel, Health Canada, Approval, Mantle Cell Lymphoma</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><a href=""https://pharmashots.com/wp-admin/post.php?post=65956&amp;action=edit""><strong>Incyte Reports EMA’s Validation of MAA for Ruxolitinib Cream to Treat Vitiligo</strong></a></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> Oct 29, 2021 | <strong>Tags:</strong> Incyte, EMA, MAA, Ruxolitinib Cream, Vitiligo</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><a href=""https://pharmashots.com/wp-admin/post.php?post=65906&amp;action=edit""><strong>Immunic Reports Completion of Patient Enrollment in P-II CALDOSE-1 Trial of IMU-838 for the Treatment of Ulcerative Colitis</strong></a></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> Oct 28, 2021 | <strong>Tags:</strong> Immunic, P-II, CALDOSE-1 Trial, IMU-838, Ulcerative Colitis</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><a href=""https://pharmashots.com/wp-admin/post.php?post=65908&amp;action=edit""><strong>Hutchmed Initiates P-III ESLIM-01 Trial of HMPL-523 for the Treatment of Immune Thrombocytopenia in China</strong></a></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> Oct 28, 2021 | <strong>Tags:</strong> Hutchmed, P-III, ESLIM-01 Trial, HMPL-523, Immune Thrombocytopenia, China</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><a href=""https://pharmashots.com/wp-admin/post.php?post=65903&amp;action=edit""><strong>Innovent Entered into a Collaboration Agreement with NeoCura to Evaluate Sintilimab + NEO_PLIN2101 for Cancer in China</strong></a></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> Oct 28, 2021 | <strong>Tags:</strong> Innovent, NeoCura, Sintilimab, NEO_PLIN2101, Cancer, China</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><a href=""https://pharmashots.com/wp-admin/post.php?post=65891&amp;action=edit""><strong>Alnylam Reports Results of Vutrisiran in P-III HELIOS-A Study for the Treatment of hATTR Amyloidosis with Polyneuropathy</strong></a></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> Oct 28, 2021 | <strong>Tags:</strong> Alnylam, Vutrisiran, P-III, HELIOS-A Study, hATTR Amyloidosis, Polyneuropathy</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><a href=""https://pharmashots.com/wp-admin/post.php?post=65892&amp;action=edit""><strong>Curacle Signs a License and Collaboration Agreement with Théa for Development and Commercialization of CU06-RE to treat Diabetic Macular Edema and Wet-AMD</strong></a></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> Oct 28, 2021 | <strong>Tags:</strong> Curacle, Théa, CU06-RE, Diabetic Macular Edema, Wet-AMD</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><a href=""https://pharmashots.com/wp-admin/post.php?post=65893&amp;action=edit""><strong>Takeda to Acquire GammaDelta to Advance the Development of Allogeneic ?dT Cell Therapies for the Treatment of Solid Tumors</strong></a></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> Oct 28, 2021 | <strong>Tags:</strong> Takeda, GammaDelta, Allogeneic ?dT Cell Therapies, Solid Tumors</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><a href=""https://pharmashots.com/wp-admin/post.php?post=65863&amp;action=edit""><strong>Merck Presents Results of Islatravir + Doravirine in P-IIb Clinical Trial for the Treatment of HIV-1 at EACS 2021</strong></a></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> Oct 27, 2021 | <strong>Tags:</strong> Merck, Islatravir, Doravirine, P-IIb, Clinical Trial, HIV-1, EACS 2021</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><a href=""https://pharmashots.com/wp-admin/post.php?post=65864&amp;action=edit""><strong>Teva Signs an Exclusive WW License Agreement with Modag to Develop Anle138b and Sery433 for Neurodegenerative Disease</strong></a></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> Oct 27, 2021 | <strong>Tags:</strong> Teva, Modag, Anle138b, Sery433, Neurodegenerative Disease</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><a href=""https://pharmashots.com/wp-admin/post.php?post=65854&amp;action=edit""><strong>Vifor and Angion’s ANG-3777 Fail to Meet its Primary and Secondary Endpoint for Patients with High-Risk Kidney Transplant</strong></a></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> Oct 27, 2021 | <strong>Tags:</strong> Vifor, Angion, ANG-3777, High-Risk Kidney Transplant,Delayed Graft Function</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><a href=""https://pharmashots.com/wp-admin/post.php?post=65843&amp;action=edit""><strong>Pfizer and BioNTech’s COVID-19 Vaccine Receive the US FDA’s Advisory Committee Vote Supporting EUA Against COVID-19</strong></a></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> Oct 27, 2021 | <strong>Tags:</strong> Pfizer, BioNTech, COVID-19 Vaccine, US, FDA, Advisory Committee, EUA, COVID-19</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><a href=""https://pharmashots.com/wp-admin/post.php?post=65844&amp;action=edit""><strong>Selecta Collaborates with Ginkgo to Develop Therapeutic Enzymes for the Treatment of Orphan and Rare Diseases</strong></a></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> Oct 27, 2021 | <strong>Tags:</strong> Selecta, Ginkgo Bioworks, Orphan, Rare Diseases, Therapeutic Enzymes</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><a href=""https://pharmashots.com/wp-admin/post.php?post=65845&amp;action=edit""><strong>Vertex Collaborates with Mammoth Biosciences to Develop In Vivo Gene-Editing Therapies for Genetic Diseases</strong></a></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> Oct 27, 2021 | <strong>Tags:</strong> Vertex, Mammoth Biosciences, In Vivo Gene-Editing Therapies, Genetic Diseases</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><a href=""https://pharmashots.com/wp-admin/post.php?post=65803&amp;action=edit""><strong>Moderna Reports Results of COVID-19 Vaccine in P-II/III KidCOVE Study for the Treatment of COVID-19</strong></a></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> Oct 26, 2021 | <strong>Tags:</strong> Moderna, COVID-19 Vaccine, mRNA-1273, P-II/III, KidCOVE Study, COVID-19</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><a href=""https://pharmashots.com/wp-admin/post.php?post=65804&amp;action=edit""><strong>Glenmark launches Remogliflozin + Vildagliptin + Metformin as Fixed Dose Combination for the Treatment of Type 2 Diabetes in India</strong></a></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> Oct 26, 2021 | <strong>Tags:</strong> Glenmark, Remogliflozin, Vildagliptin, Metformin, Type 2 Diabetes, India</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><a href=""https://pharmashots.com/wp-admin/post.php?post=65805&amp;action=edit""><strong>Guardant Health Presents Results of LUNAR-2 Blood Test for the Treatment of Early-Stage Colorectal Cancer at ACG 2021</strong></a></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> Oct 26, 2021 | <strong>Tags:</strong> Guardant Health, LUNAR-2 Blood Test, Early-Stage Colorectal Cancer, ACG 2021</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><a href=""https://pharmashots.com/wp-admin/post.php?post=65792&amp;action=edit""><strong>MSD Entered into a Clinical Trial Collaboration with Evaxion to Evaluate EVX-01 + Keytruda (pembrolizumab) for Metastatic Melanoma</strong></a></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> Oct 26, 2021 | <strong>Tags:</strong> MSD, Evaxion, EVX-01, Keytruda, pembrolizumab, Metastatic Melanoma</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><a href=""https://pharmashots.com/wp-admin/post.php?post=65793&amp;action=edit""><strong>AstraZeneca Reports Results of Imfinzi in P-III TOPAZ-1 Trial as 1L Treatment for Advanced Biliary Tract Cancer</strong></a></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> Oct 26, 2021 | <strong>Tags:</strong> AstraZeneca, Imfinzi, P-III, TOPAZ-1 Trial, Advanced Biliary Tract Cancer</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><a href=""https://pharmashots.com/wp-admin/post.php?post=65791&amp;action=edit""><strong>Daiichi Sankyo and AstraZeneca Entered into a Second Clinical Trial Collaboration with Merck for Datopotamab Deruxtecan (Dato-DXd) + Keytruda (pembrolizumab)</strong></a></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> Oct 26, 2021 | <strong>Tags:</strong> Daiichi Sankyo, AstraZeneca, Merck, Datopotamab Deruxtecan, Dato-DXd, Keytruda, pembrolizumab, Metastatic NSCLC</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><a href=""https://pharmashots.com/wp-admin/post.php?post=65755&amp;action=edit""><strong>Merck Reports Results of Doravirine/Islatravir as Fixed Dose Combination in P-III Trials for the Treatment of HIV-1 Infection</strong></a></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> Oct 25, 2021 | <strong>Tags:</strong> Merck, Doravirine, Islatravir, Fixed Dose Combination, P-III, Trials, HIV-1 Infection</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><a href=""https://pharmashots.com/wp-admin/post.php?post=65756&amp;action=edit""><strong>Merck and Ridgeback Report the Initiation of EMA Rolling Review of Molnupiravir for the Treatment of COVID-19</strong></a></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> Oct 25, 2021 | <strong>Tags:</strong> Merck, Ridgeback, EMA, Molnupiravir, COVID-19</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><a href=""https://pharmashots.com/wp-admin/post.php?post=65757&amp;action=edit""><strong>Novartis Reports Results of Canakinumab in P-III CANOPY-1 Study for the Treatment of Lung Cancer</strong></a></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> Oct 25, 2021 | <strong>Tags:</strong> Novartis, Canakinumab, P-III, CANOPY-1 Study, Lung Cancer</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><a href=""https://pharmashots.com/wp-admin/post.php?post=65747&amp;action=edit""><strong>Regeneron and Sanofi Report Results of Dupixent (dupilumab) in P-III Trial for the Treatment of Eosinophilic Esophagitis</strong></a></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> Oct 25, 2021 | <strong>Tags:</strong> Regeneron, Sanofi, Dupixent, dupilumab, P-III, Trial, Eosinophilic Esophagitis</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><a href=""https://pharmashots.com/wp-admin/post.php?post=65742&amp;action=edit""><strong>Agenus Reports the Withdrawal of BLA for Balstilimab to Treat Cervical Cancer</strong></a></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> Oct 25, 2021 | <strong>Tags:</strong> Agenus, Withdrawal, BLA, Balstilimab, Cervical Cancer</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><a href=""https://pharmashots.com/wp-admin/post.php?post=65743&amp;action=edit""><strong>Genentech’s Susvimo Receives the US FDA’s Approval for the Treatment of Wet Age-Related Macular Degeneration</strong></a></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> Oct 25, 2021 | <strong>Tags:</strong> Genentech, Susvimo, US, FDA, Approval, Wet Age-Related Macular Degeneration</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Related Post: <a href=""https://pharmashots.com/65735/pharmashots-weekly-snapshots-october-18-22-2021/"">PharmaShots Weekly Snapshots (October 18 – 22, 2021)</a></strong></p>
<!-- /wp:paragraph -->",,https://pharmashots.com/wp-content/uploads/2021/10/MicrosoftTeams-image-117.png,Weekly Snapshot,,,AbbVie|ADC|Agenus|Alnylam|Angion|AstraZeneca|BioNTech|Curacle|Daiichi Sankyo|GammaDelta|Genentech|Ginkgo Bioworks|Glenmark|Guardant Health|Hutchmed|Immunic|Impact|Incyte|Innovent|Kite|Mammoth Biosciences|Merck|Modag|Moderna|MSD|NeoCura|Novartis|Pfizer|Ridgeback|Selecta|Takeda|Teva|Théa|Vertex|Vifor,publish,29-10-2021,17
66157,"PharmaShots Weekly Snapshots (November 01 – 03, 2021)",,"<!-- wp:paragraph -->
<p><a href=""https://pharmashots.com/wp-admin/post.php?post=66119&amp;action=edit""><strong>Lonza Collaborates with Codiak to Acquire its Exosomes Manufacturing Facility in Lexington, Massachusetts (US)</strong></a></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> Nov 3, 2021 | <strong>Tags:</strong> Lonza, Codiak, Acquire, Exosomes Manufacturing Facility, Lexington, Massachusetts, US</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><a href=""https://pharmashots.com/wp-admin/post.php?post=66120&amp;action=edit""><strong>Amylyx Submits NDA to the US FDA for AMX0035 to Treat Amyotrophic Lateral Sclerosis</strong></a></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> Nov 3, 2021 | <strong>Tags:</strong> Amylyx, NDA, US, FDA, AMX0035, ALS</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><a href=""https://pharmashots.com/wp-admin/post.php?post=66121&amp;action=edit""><strong>uniQure Provides Positive Recommendation to Advance P- I/II Study of AMT-130 for Huntington Disease</strong></a></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> Nov 3, 2021 | <strong>Tags:</strong> uniQure, P- I/II, Study, AMT-130, Huntington Disease</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><a href=""https://pharmashots.com/wp-admin/post.php?post=66103&amp;action=edit""><strong>Ionis Initiates P-III CORE Study of Olezarsen for the Treatment of Severe Hypertriglyceridemia</strong></a></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> Nov 3, 2021 | <strong>Tags:</strong> Ionis, P-III, CORE Study, Olezarsen, Severe Hypertriglyceridemia</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><a href=""https://pharmashots.com/wp-admin/post.php?post=66104&amp;action=edit""><strong>Roche Entered into a Clinical Trial Supply Agreement with Galecto to Evaluate GB1211 + Tecentriq (atezolizumab) in P-IIa Trial for 1L Treatment of NSCLC</strong></a></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> Nov 3, 2021 | <strong>Tags:</strong> Roche, Galecto, GB1211, Tecentriq, atezolizumab, P-IIa, Trial, NSCLC</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><a href=""https://pharmashots.com/wp-admin/post.php?post=66105&amp;action=edit""><strong>Novartis Entered into a Collaboration and License Agreement with Dunad to Develop Oral Targeted Protein Degrader Therapies</strong></a></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> Nov 3, 2021 | <strong>Tags:</strong> Novartis, Dunad, Oral Targeted, Protein Degrader Therapies</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><a href=""https://pharmashots.com/wp-admin/post.php?post=66073&amp;action=edit""><strong>Moderna Entered into a Research and Development Collaboration with Metagenomi to Develop In Vivo Gene Editing Therapeutics</strong></a></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> Nov 2, 2021 | <strong>Tags:</strong> Moderna, Metagenomi, In Vivo Gene Editing Therapeutics, Genetic Diseases</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><a href=""https://pharmashots.com/wp-admin/post.php?post=66074&amp;action=edit""><strong>Antengene’s Receives NMPA’s IND Approval for P-Ib MATCH Study of ATG-008 (onatasertib) ATG-010 (selinexor) to Treat Diffuse Large B-Cell Lymphoma</strong></a></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> Nov 2, 2021 | <strong>Tags:</strong> Antengene, NMPA, IND, Approval, P-Ib, MATCH Study, ATG-008, onatasertib, ATG-010, Selinexor, Diffuse Large B-Cell Lymphoma</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><a href=""https://pharmashots.com/wp-admin/post.php?post=66075&amp;action=edit""><strong>AstraZeneca Reports Results of Saphnelo in P-III TULIP Clinical Trial Program for the Treatment of Systemic Lupus Erythematosus</strong></a></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> Nov 2, 2021 | <strong>Tags:</strong> AstraZeneca, Saphnelo, P-III, TULIP Clinical Trial Program, Systemic Lupus Erythematosus</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><a href=""https://pharmashots.com/wp-admin/post.php?post=66061&amp;action=edit""><strong>Janssen Reports Results of Tremfya (guselkumab) in P-III DISCOVER-1 &amp; 2 Trials for the Treatment of Active Psoriatic Arthritis</strong></a></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> Nov 2, 2021 | <strong>Tags:</strong> Janssen, Tremfya, guselkumab, P-III, DISCOVER-1, 2, Trials, Active Psoriatic Arthritis</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><a href=""https://pharmashots.com/wp-admin/post.php?post=66062&amp;action=edit""><strong>Junshi and Coherus Report the US FDA Acceptance of BLA for Toripalimab to Treat Nasopharyngeal Carcinoma</strong></a></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> Nov 2, 2021 | <strong>Tags:</strong> Junshi, Coherus, US, FDA, BLA, Toripalimab, Nasopharyngeal Carcinoma</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><a href=""https://pharmashots.com/wp-admin/post.php?post=66063&amp;action=edit""><strong>Merck Entered into a WW Research Collaboration and License Agreement with Synthekine to Develop Novel Cytokine Therapeutics</strong></a></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> Nov 2, 2021 | <strong>Tags:</strong> Merck, Synthekine, Cytokine Therapeutics, Autoimmune Diseases</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><a href=""https://pharmashots.com/wp-admin/post.php?post=66032&amp;action=edit""><strong>Incyte Reports the US FDA’s Acceptance of NDA for Parsaclisib to Treat R/R Non-Hodgkin Lymphomas</strong></a></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> Nov 1, 2021 | <strong>Tags:</strong> Incyte, US, FDA, NDA, Parsaclisib, R/R Non-Hodgkin Lymphomas</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><a href=""https://pharmashots.com/wp-admin/post.php?post=66029&amp;action=edit""><strong>AstraZeneca to Divest Global Rights of Eklira and Duaklir to Covis Pharma in $270M Deal</strong></a></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> Nov 1, 2021 | <strong>Tags:</strong> AstraZeneca, Eklira, Duaklir, Covis Pharma, $270M</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><a href=""https://pharmashots.com/wp-admin/post.php?post=66020&amp;action=edit""><strong>AstraZeneca and Hutchmed Initiate P-III SAMETA Trial of Imfinzi (durvalumab) + Orpathys (savolitinib) for Advanced Papillary Renal Cell Carcinoma</strong></a></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> Nov 1, 2021 | <strong>Tags:</strong> AstraZeneca, Hutchmed, P-III, SAMETA Trial, Imfinzi, durvalumab, Savolitinib, Advanced Papillary Renal Cell Carcinoma</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><a href=""https://pharmashots.com/wp-admin/post.php?post=66008&amp;action=edit""><strong>Novartis’ Scemblix (asciminib) Receives the US FDA’s Approval for the Treatment of Chronic Myeloid Leukemia</strong></a></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> Nov 1, 2021 | <strong>Tags:</strong> Novartis, Scemblix, asciminib, US, FDA, Approval, Chronic Myeloid Leukemia</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><a href=""https://pharmashots.com/wp-admin/post.php?post=66005&amp;action=edit""><strong>Merck Presents New Data of Keytruda (pembrolizumab) in Three Studies for the Treatment of Melanoma at SMR 2021</strong></a></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> Nov 1, 2021 | <strong>Tags:</strong> Merck, Keytruda, pembrolizumab, Studies, Melanoma, SMR 2021</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><a href=""https://pharmashots.com/wp-admin/post.php?post=66001&amp;action=edit""><strong>Gilead Reports Interim Results of Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) in BICSTaR Study to Treat HIV</strong></a></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Published:</strong> Nov 1, 2021 | <strong>Tags:</strong> Gilead, Biktarvy, bictegravir, emtricitabine, tenofovir alafenamide, BICSTaR Study, HIV</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Related Post:</strong> <strong><a href=""https://pharmashots.com/65986/pharmashots-weekly-snapshots-october-25-29-2021/"">PharmaShots Weekly Snapshots (October 25 – 29, 2021)</a></strong></p>
<!-- /wp:paragraph -->",,https://pharmashots.com/wp-content/uploads/2021/11/MicrosoftTeams-image-124.jpg,Weekly Snapshot,,,Amylyx|Antengene|AstraZeneca|Codiak|Coherus|Dunad|Galecto|Gilead|Hutchmed|Incyte|Ionis|Janssen|Junshi|Lonza|Merck|Metagenomi|Moderna|Novartis|Roche|Synthekine|uniQure,publish,05-11-2021,17
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
